<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103917</url>
  </required_header>
  <id_info>
    <org_study_id>X4P-001-201</org_study_id>
    <nct_id>NCT05103917</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC</brief_title>
  <official_title>An Open Label, Phase Ib/II Trial to Study the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With Toripalimab in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbisko Therapeutics Co, Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbisko Therapeutics Co, Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives Phase 1b&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
      To evaluate the safety and tolerability of X4P-001 combined with toriplimab in patients with&#xD;
      locally advanced or metastatic TNBC&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To characterize the pharmacokinetics (PK) profile of X4P-001 alone or combined with&#xD;
           toriplimab&#xD;
&#xD;
        2. To characterize the antitumor activity of X4P-001 in combination with toriplimab in&#xD;
           patients with locally advanced or metastatic TNBC(according to RECIST 1.1)&#xD;
&#xD;
        3. To characterize the overall survival of X4P-001 in combination with toriplimab in&#xD;
           patients with locally advanced or metastatic TNBC&#xD;
&#xD;
        4. To characterize the immunogenicity of toriplimab when administrated in combination with&#xD;
           X4P-001&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exploratory Objectives:&#xD;
&#xD;
        1. To explore selected biomarkers in peripheral blood and tumor samples that potentially&#xD;
           correlate with clinical response to X4P-001 and toriplimab combination treatment&#xD;
&#xD;
        2. To characterize the antitumor activity of X4P-001 in combination with toriplimab in&#xD;
           patients with locally advanced or metastatic TNBC(according to iRECIST 1.1)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Anticipated">May 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CT</measure>
    <time_frame>Screening</time_frame>
    <description>resist 1.1 evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CT</measure>
    <time_frame>C3D1 (12 weeks)</time_frame>
    <description>resist 1.1 evaluation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>X4P-001-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trial to Study the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination with Toripalimab in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>X4P-001</intervention_name>
    <description>CXCR4 inhibitor</description>
    <arm_group_label>X4P-001-201</arm_group_label>
    <other_name>Toripalimab Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Female, age 18 ~ 75 (including both ends, or other age range required by local&#xD;
             regulations or IRB).&#xD;
&#xD;
             2. Patients must have histological confirmed locally advanced or metastatic TNBC:&#xD;
&#xD;
             a) The primary or metastatic lesions were pathologically confirmed to be triple&#xD;
             negative, that is, negative for ER, PR and HER-2. Negative ER and PR are defined as ER&#xD;
             &lt; 1% positive and PR &lt; 1% positive. HER-2 negative is defined as: immunohistochemical&#xD;
             detection of HER-2 (-) or (1 +), HER-2 (2 +) must be tested for FISH and the result is&#xD;
             negative, HER-2 (1 +) can be selected for FISH test and the result is negative, and&#xD;
             metastatic pathology is preferred b) Patient must have at least 1 measurable lesion&#xD;
             (by RECIST V1.1) c) Patient must progress after first-line and not more than&#xD;
             second-line systematic treatment d) Patient must agree to undergo a tumor biopsy in&#xD;
             the study e) Previous tumor tissue samples that meet the requirements should be&#xD;
             provided during the screening period, or tumor biopsies should be performed before the&#xD;
             first treatment.&#xD;
&#xD;
             3. ECOG performance status 0~1 4. Life expectancy ≥ 12 weeks 5. Adequate organ&#xD;
             function and bone marrow function as indicated by the following screening assessments&#xD;
             performed within 14 days before the first dose of study drug (without blood&#xD;
             transfusion or medication with stimulation factors within 14 days before 1st dose) :&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1.5×109/L&#xD;
&#xD;
               2. Platelet count (PLT) ≥100×109/L&#xD;
&#xD;
               3. Hemoglobin (Hb) ≥90 g/L&#xD;
&#xD;
               4. Total bilirubin (TBIL) ≤1.5×ULN&#xD;
&#xD;
               5. Aspartate transaminase (AST) and alanine transaminase (ALT), ≤2.5 ×ULN (for the&#xD;
                  patient with liver metastasis in escalation part or patient in expansion part:&#xD;
                  AST and AST ≤5×ULN)&#xD;
&#xD;
               6. Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (Crcl) ≥50mL/min based on&#xD;
                  Cockcroft-Gault formula 6. Female patients of childbearing potential must agree&#xD;
                  to use effective methods of birth control during the study and for up to 6 months&#xD;
                  after the last dose of study drug. Non-surgically sterilized female patients of&#xD;
                  childbearing potential must be in non-lactation period, and have a negative β-HCG&#xD;
                  test result within 7 days before first administration.&#xD;
&#xD;
                  7. Patient should understand, sign, and date the written voluntary informed&#xD;
                  consent form prior to any protocol-specific procedures performed. Patient should&#xD;
                  be able and willing to comply with study visits and procedures as per protocol.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients who are known to be allergic to any component of X4P-001 or triplizumab or&#xD;
             have previously developed severe allergic reactions, rapid allergic reactions or other&#xD;
             hypersensitivity to peptides, chimeric or humanized antibodies, fusion proteins 2.&#xD;
             Patients who suffer from other malignant tumors within 5 years before enrollment&#xD;
             (except: radical cervical carcinoma in situ or non-melanoma skin cancer; second&#xD;
             primary cancer that has been cured and has no recurrence within five years; the&#xD;
             researchers believe that both primary cancers can benefit from this study; the&#xD;
             researchers have clearly confirmed which primary tumor source the metastatic focus&#xD;
             belongs to).&#xD;
&#xD;
             3. Patients with primary central nervous system malignant tumor; patients with central&#xD;
             nervous system metastasis who failed local treatment; (patients with asymptomatic&#xD;
             brain metastasis, or patients with stable clinical symptoms and without steroids and&#xD;
             other treatment for brain metastasis for more than 28 days can be included in the&#xD;
             group. ).&#xD;
&#xD;
             4. Patients who use cytochrome P450 (CYP) 3A4, strong 2D6 inhibitors or inducers (see&#xD;
             12.4, including prohibited foods) and antacids before the first use, and the last use&#xD;
             is less than 14 days or 5 half-lives from the first use, whichever is the shorter.&#xD;
&#xD;
             5. Patient who RANKL ligand inhibitors were used within 1 month before the first&#xD;
             administration of the study drug or are expected to be used during the study period&#xD;
             (e.g. deschumab, etc.) 6. Patients who systemic immunosuppressive drugs (including,&#xD;
             but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate,&#xD;
             thalidomide, etc.) are used within 2 weeks prior to the first administration of&#xD;
             research drugs, or systemic immunosuppressive drugs are known to be required in the&#xD;
             course of research treatment, unless:&#xD;
&#xD;
               1. Patients who receive short-term, low-dose systemic immunosuppressive drugs or&#xD;
                  patients who receive one-time systemic immunosuppressive drug pulse therapy (such&#xD;
                  as corticosteroids for 48 hours for the treatment of contrast medium allergic&#xD;
                  reactions, single use of cyclophosphamide during induction of tumor therapeutic&#xD;
                  vaccine)&#xD;
&#xD;
               2. Patients who receive corticosteroids in the treatment of chronic obstructive&#xD;
                  pulmonary disease or asthma, or low-dose corticosteroids in the treatment of&#xD;
                  orthostatic hypotension or adrenal insufficiency are allowed to enter the group&#xD;
                  7. Previous anti-cancer therapy prior to initiation of study treatment: major&#xD;
                  surgery (except palliative therapy), radiotherapy (bone-marrow exposure&#xD;
                  &gt;30%);routine chemotherapy, targeted therapy, immunotherapy is less than 4 weeks&#xD;
                  (chemotherapy with nitrosourea or mitomycin &lt;6 weeks); endocrine therapy within ≤&#xD;
                  5 half-life or ≤ 14 days (whichever is shorter).&#xD;
&#xD;
                  8. Patients who are unable to take oral drugs or there are factors that&#xD;
                  significantly affect oral drug absorption, such as gastric remnant dysfunction&#xD;
                  after previous total gastrectomy or subtotal gastrectomy, short bowel syndrome&#xD;
                  after small bowel resection, active diarrhea or irritable bowel syndrome&#xD;
                  requiring drug treatment, etc.&#xD;
&#xD;
                  9. Patients with previous organ transplants 10. Patients with definite active&#xD;
                  infection or fever of unknown origin &gt; 38.3 ℃ within 4 weeks before receiving the&#xD;
                  first study drug and were treated with oral or intravenous antibiotics.&#xD;
&#xD;
                  11. Patients who had previously participated in other clinical studies were&#xD;
                  included in the original clinical study and less than 28 days after the first&#xD;
                  administration of the drug in this study.&#xD;
&#xD;
                  12. Patients whose adverse events caused by previous antineoplastic therapy did&#xD;
                  not recover to ≤ grade 1 (CTCAE5.0) (except for alopecia, vitiligo, ≤ grade 2&#xD;
                  neurotoxicity and other events that researchers believe do not affect the safety&#xD;
                  evaluation of patients and research drugs).&#xD;
&#xD;
                  13. Impaired cardiac function or clinically significant cardiac disease,&#xD;
                  including any of the following:&#xD;
&#xD;
             a) New York Heart Association class III or IV congestive heart failure, unstable&#xD;
             angina, or myocardial infarction within 6 months before administration of the study&#xD;
             drug; b) Clinically significant cardiac arrhythmia requiring active therapy; c)&#xD;
             Uncontrolled hypertension; d) Left ventricle ejection fraction&lt;50%; e) Prolongation of&#xD;
             QTcF (average of three times of examine, male &gt; 450 ms, female &gt; 470 ms) (Note: QTc&#xD;
             interval corrected by Frederica's formula) at screening, and other ECG abnormalities&#xD;
             with clinical significant by the judge of the investigator.&#xD;
&#xD;
             14. Patients with a history of interstitial pneumonia 15. Patients were positive for&#xD;
             (HIV) antibody of human immunodeficiency virus, (HCV) antibody of hepatitis C virus&#xD;
             and (TP) antibody of Treponema pallidum, and (HBV) surface antigen of hepatitis B&#xD;
             virus was positive and HBVDNA ≥ 1000IU/ml. The subjects are in active stage of&#xD;
             tuberculosis; (antiviral therapy is allowed during the trial of subjects with positive&#xD;
             (HBV) surface antigen of hepatitis B virus).&#xD;
&#xD;
             16. Any other clinically significant comorbidities, such as respiratory, metabolic,&#xD;
             congenital, endocrine or central nervous system disease, or any other medical&#xD;
             conditions, mental disturbances or social determinants, which in the judgment of the&#xD;
             Investigator, could compromise compliance with the protocol, interfere with the&#xD;
             interpretation of study results, or predispose the patient to safety risks.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J L Zheng, Director</last_name>
    <role>Study Director</role>
    <affiliation>Abbisko Therapeutics Co, Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shang hai Tumor Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shang Hai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

